I mmunoglobulin E Ab-mediated allergy affects .25% of the population (1) . Since the first clinical trial conducted by Leonard Noon in patients allergic to grass pollen .100 y ago, allergen-specific immunotherapy (SIT) is the only Ag-specific and disease-modifying treatment for allergy (2, 3) . SIT is based on the administration of the disease-causing allergens with the goal to reduce allergic inflammation upon allergen exposure. Furthermore, it was shown that SIT can prevent the progression from mild to severe forms of allergy and that it has long-lasting effects, even after its discontinuation (4, 5) . Major immunological mechanisms underlying SIT are the induction of allergen-specific IgG Abs that inhibit IgE-mediated allergic inflammation and alterations in cellular responses, including the induction of IL-10-producing regulatory T cells, shifts toward Th1 responses, and effects on APCs and effector cells (e.g., mast cells, basophils) (3) .
However, several disadvantages, which are mainly due to the poor quality of allergen preparations, limit the broad applicability of SIT. They include varying allergen compositions, cumbersome forms of treatment requiring multiple injections, and severe anaphylactic side effects due to varying potency of vaccines (6) (7) (8) (9) (10) (11) .
With the identification of allergen structures by cDNA cloning it has become possible to produce recombinant allergens to study allergen-specific immune responses, as well as to develop new forms of diagnosis and new approaches of SIT that target different immunological mechanisms (12, 13) . Several of these molecular approaches were tested in clinical trials in allergic patients. As exemplified for the major cat allergen, Fel d 1, induction of allergen-specific T cell tolerance in allergic patients by administration of synthetic allergen-derived, non-IgE-reactive peptides was attempted (14, 15) . Other approaches were based on vaccination with recombinant hypoallergenic allergen derivatives, highly purified recombinant allergens, or purified allergens conjugated to immunomodulatory substances (16) (17) (18) .
It was demonstrated for birch pollen allergy that SIT with the recombinant major allergen of birch, Bet v 1, is equally effective as SIT with birch pollen extract or natural purified Bet v 1 (19) .
Birch pollen is one of the most important inhalant allergen sources in northern and central Europe, North America, and certain parts of Asia and Australia. The cDNA coding for Bet v 1 was isolated (20) , rBet v 1 equaling natural Bet v 1 (21) was produced, and the major T cell epitopes of Bet v 1 were mapped (22) . The three-dimensional structure of Bet v 1 was solved using x-ray and nuclear magnetic resonance technology (23) . Bet v 1 contains mainly conformational IgE epitopes that are lost when its structure and fold are destroyed (24) . Using site-directed mutagenesis and epitope mapping based on peptide-specific Abs, it was shown that a surface patch defined by peptides comprising aa 49-58, 73-88, and 88-103 of Bet v 1 represents a major IgE binding site (25, 26) .
In this article, we report the construction and characterization of a nonallergenic vaccine for birch pollen allergy that is based on recombinant fusion proteins consisting of nonallergenic peptides derived from the major IgE-binding area of Bet v 1 and the viral carrier molecule PreS derived from hepatitis B. In addition to a reduction in IgE reactivity, T cell reactivity, and allergenic activity, which together should decrease IgE-and T cell-mediated side effects during SIT, our study reveals important novel and unique features of this vaccine. In contrast to Bet v 1, which induced Th2 responses in patients' PBMCs, the fusion proteins led to production of the tolerogenic cytokine IL-10 and to Th1-biased immune responses. Moreover, immunization with the fusion proteins focused blocking IgG Abs better toward the major IgE epitopes than did immunization with the complete Bet v 1 allergen.
Materials and Methods
Recombinant allergens, synthetic peptides, and allergic patients rBet v 1, rAln g 1, rCor a 1, and rMal d 1 were purchased from BIOMAY (Vienna, Austria). Bet v 1-derived peptides PA, PB, P19, P29, P39, P49, P59, and P69 (Fig. 1A) were synthesized and purified as described (25) . Serum and heparinized blood samples were obtained from patients allergic to birch pollen (n = 54) and, for control purposes, from nonallergic individuals (n = 3) after informed consent and approval of the local ethics committee were obtained. Allergic patients were characterized by case history, determination of allergen-specific IgE, and/or skin testing, as described (27) .
Expression and purification of rPreS and rPreS fusion proteins
DNAs coding for fusion proteins consisting of PreS fused with Bet v 1-derived peptides (Fig. 1B) , which were codon optimized for expression in Escherichia coli, were synthesized (2PA-PreS, 2PB-PreS, 4PA-PreS: ATG: biosynthetics, Merzhausen, Germany; 2PAPB-PreS: GenScript, Piscataway, NJ) and inserted into the NdeI/XhoI sites of plasmid pET-27b (Novagen, Darmstadt, Germany). The DNA sequences were confirmed by DNA sequencing of both strands (Microsynth, Balgach, Switzerland).
rPreS and rPreS fusion proteins were expressed in E. coli strain BL21 (DE3) (Stratagene, La Jolla, CA) by growing transformed cells in liquid Luria-Bertani medium containing 50 mg/ml kanamycin to an OD of 0.6. Protein expression was then induced by adding isopropyl-b-D-thio-galactopyranoside to a final concentration of 1 mmol/l overnight at 37˚C. Cells were harvested by centrifugation. For PreS, 2PA-PreS, and 2PB-PreS inclusion bodies were prepared, whereas for 4PA-PreS and 2PAPB-PreS the bacterial cell pellets were dissolved directly in 6 M GuHCl, 100 mM NaH 2 PO 4 , and 10 mM Tris [pH 8]. Recombinant proteins were purified by nickel-affinity chromatography, as described (28) . Fusion proteins were eluted with 8 mol/l urea, 100 mmol/l NaH 2 PO 4 , and 10 mmol/l Tris-HCl (pH 3.5); after dialysis either against water (2PA-PreS, 2PB-PreS, 4PA-PreS) or against 10 mM NaH 2 PO 4 (pH 4.8) (PreS, 2PAPB-PreS) they remained soluble at a concentration of 1 mg/ml.
Characterization of rPreS and rPreS fusion proteins
The purity of recombinant proteins was analyzed by SDS-PAGE (12.5%) and subsequent Coomassie staining (29) .
Molecular weights of PreS and PreS fusion proteins were compared with those calculated according to their sequence using Expasy (http://www. expasy.org).
Aliquots of 1 mg PreS fusion proteins, PreS, and human serum albumin (HSA; control) were dotted onto nitrocellulose and incubated with mAbs specific for peptide P29 (mAb2) or P49 (mAb12), as well as with rabbit Ig specific for PreS or the corresponding preimmune Ig diluted 1:1000 at 4˚C (26) . Bound mouse and rabbit Abs were detected with 125 I-labeled rabbit anti-mouse and 125 I-labeled goat anti-rabbit IgG, respectively (PerkinElmer, Waltham, MA), diluted 1:500 for 2 h and visualized by autoradiography (30) .
IgE reactivity of PreS fusion proteins determined by radioallergosorbent test-based dot blot and ELISA Purified rBet v 1, recombinant fusion proteins, and PreS were tested for IgE reactivity by radioallergosorbent test-based, nondenaturing dot blot assays. Two micrograms of the purified proteins and, for control purposes, HSA were dotted onto nitrocellulose membrane strips (Schleicher & Schuell, Dassel, Germany), which were blocked in buffer A (31) and then incubated with 1:10 diluted sera from patients allergic to birch pollen (n = 47), sera from nonallergic persons (n = 3), or buffer alone. Bound IgE Abs were detected with 125 I-labeled anti-human IgE Abs (Demeditec, KielWellsee, Germany). The presence of rBet v 1 and PreS fusion proteins on the nitrocellulose was demonstrated using a 1:1000 diluted rabbit antirBet v 1 antiserum, followed by 125 I-labeled goat anti-rabbit Abs (PerkinElmer) and visualization by autoradiography (30) .
In additional IgE-binding experiments, ELISA plates were coated with rBet v 1 or with the purified PreS fusion proteins (5 mg/ml) diluted in 0.1 mol/l carbonate buffer (pH 9.6) overnight at 4˚C. Plates were washed three times with PBS containing 0.05% (v/v) Tween 20 (PBST), blocked for 2 h with 1% (w/v) BSA in PBST, and subsequently incubated with sera from patients allergic to birch pollen (n = 21) and three nonallergic individuals diluted 1:5. Bound IgE was detected with purified mouse anti-human IgE (BD Pharmingen, Franklin Lakes, NJ) diluted 1:1000 overnight and visualized with HRP-labeled sheep anti-mouse IgG (GE Healthcare, Buckinghamshire, U.K.) diluted 1:2000 (25) . Results (i.e., OD values corresponding to bound IgE) are means of duplicate determinations with a variation ,10%. The blank control (i.e., OD from empty wells developed with the color substrate) was subtracted.
Allergen-induced upregulation of CD203c on basophils of allergic patients
Heparinized blood samples were obtained from patients allergic to birch pollen (n = 6) after informed consent was given; they were incubated with increasing concentrations of rBet v 1, 2PA-PreS, 2PB-PreS, 4PA-PreS, or 2PAPB-PreS (0.00001-0.1 mg/ml), with a monoclonal anti-IgE Ab (1 mg/ ml; Immunotech, Marseille, France) or PBS alone (negative control) for 15 min (37˚C). Upregulation of CD203c expression was determined as described (32) , and results (stimulation index [SI] ) are displayed as means of triplicate determinations 6 SD.
Lymphocyte proliferation and cytokine responses of PBMCs from patients allergic to birch pollen PBMCs from patients allergic to birch pollen (n = 6) were isolated by Ficoll (Amersham Biosciences, Uppsala, Sweden) density-gradient centrifugation, resuspended in AIM V medium (Life Technologies, Grand Island, NY; 2 3 10 5 cells/well), and stimulated with 2.5 mg/well rBet v 1, with equimolar concentrations of PA, PB, PreS, 2PA-PreS, 2PB-PreS, 4PA-PreS, or 2PAPB-PreS, medium alone (negative control), or IL-2 (4 IE/ well; positive control). Endotoxin contents of proteins were determined by Endosafe Technology (Charles River, Kiselegg, Germany) and were found to range at low levels (PreS: 0.16 EU/l; 2PA-PreS: 2.00 EU/l; 2PB-PreS: 0.44 EU/l; 4PA-PreS: 6.28 EU/l; 2PAPB-PreS: 0.78 EU/l; Bet v 1: 0.05 EU/l; PA: 0.01 EU/l; PB: 0.01 EU/well). After 6 d of culture, proliferative responses were measured by [ (Biosource, Nivelles, Belgium), and the data were acquired using Bio-Plex Manager 6.0 software. All samples were analyzed in one run.
The Mann-Whitney U test was used to determine differences in SI. To calculate the variations in cytokine measurements, data were transformed into a logarithmic scale to achieve a normal distribution, and one-way ANOVA was used to visualize intersubject variability. A p value , 0.05 was considered statistically significant. SPSS Version 17 was used to calculate all statistical analyses.
Rabbit Abs specific for PreS fusion proteins
Specific rabbit anti-sera were obtained by immunization of New Zealand white rabbits three times in monthly intervals with 200 mg purified rAgs (i.e., 2PA-PreS, 2PB-PreS, 4PA-PreS, 2PAPB-PreS, rBet v 1) adsorbed either to aluminum hydroxide or to Freund's adjuvant (once with CFA, twice with IFA) (Charles River Breeding Laboratories, Kissleg, Germany). For determination of Bet v 1-specific IgG Ab responses, ELISA plates (MaxiSorp; Nunc, Roskilde, Denmark) were coated with rBet v 1 (2 mg/ ml) diluted in 0.1 mol/l carbonate buffer (pH 9.6). Plates were washed three times with PBST, blocked for 2 h with 1% (w/v) BSA-PBST, and subsequently incubated with serial 1:2 dilutions of rabbit Abs ranging from 1:500 to 1:1,280,000 overnight at 4˚C. After washing the plates five times, bound rabbit IgG Abs were detected with HRP-labeled donkey anti-rabbit Abs (GE Healthcare), and the color reaction was developed as described (25, 34) . Results (OD values corresponding to bound IgG Abs) are means of duplicate determinations with variations ,5%.
Cross-reactivity and epitope specificity of rabbit Abs were also analyzed by ELISA using rBet v 1 (birch), rAln g 1 (alder), rCor a 1 (hazel), rMal d 1 (apple), and synthetic peptides P19-P69, which had been coated at a concentration of 1 mg/ml. After washing and blocking, 1:1000 diluted antisera were added, and bound rabbit IgG was detected with HRP-labeled donkey anti-rabbit Abs (GE Healthcare).
Inhibition of allergic patients' IgE binding to rBet v 1
The inhibition of the binding of IgE from patients allergic to birch pollen to rBet v 1 was determined by an IgE-inhibition ELISA (26, 35) . ELISA plates were coated with rBet v 1 at a concentration of 1 mg/ml at 4˚C overnight. After washing and blocking, plates were preincubated with protein Gpurified (Immunopure [G] IgG Purification Kit, Pierce, Rockford, IL) rabbit anti-2PAPB-PreS, rabbit anti-PreS, or anti-Bet v 1 IgG obtained by immunization with alum-adsorbed Ags overnight at 4˚C. IgG Ab preparations were diluted according to titration experiments to contain the same concentrations of Bet v 1-specific IgG Abs (∼300 mg/ml). For control purposes, plates were incubated with the corresponding rabbit preimmune IgG. After an additional washing step, 1:5 diluted sera from patients allergic to birch pollen were added overnight at 4˚C, and bound human IgE Abs were detected with a 1:1000 diluted alkaline phosphatase-conjugated mouse monoclonal anti-human IgE Ab (BD Pharmingen). The percentages of inhibition of IgE binding to rBet v 1 after preincubation with anti-2PAPB-PreS rabbit IgG, anti-Bet v 1 rabbit IgG, and anti-PreS rabbit IgG were calculated for each patient serum as follows: percentage inhibition = 100 2 (OD i 3 100/OD p ). OD p and OD i represent the extinctions after preincubation with specific rabbit IgG (OD 
Inhibition of allergen-induced upregulation of CD203c
Whether anti-2PAPB-PreS or anti-Bet v 1 rabbit IgG can inhibit Bet v 1-induced upregulation of CD203c on basophils of patients allergic to birch pollen was studied by exposing heparinized blood samples from the patients with increasing concentrations of rBet v 1 (0.0000132-0.01 mg/ml), which were preincubated at 37˚C for 30 min with 9% rabbit anti-2PAPB-PreS or anti-Bet v 1 Abs, obtained by immunization with CFA-adsorbed Ags. For control purposes, allergen dilutions were preincubated with 9% of a serum from a rabbit without Bet v 1-specific IgG (i.e., nonimmunized rabbit). Rabbit anti-sera were heat-inactivated at 56˚C for 30 min for these experiments. CD203c upregulation was analyzed as described in Ref. 32 .
IgE-facilitated allergen-binding assay
The inhibition of IgE-facilitated binding of Bet v 1 to CD23-expressing B cells by anti-2PAPB-PreS, anti-PreS, or anti-Bet v 1 IgG was determined as described (36) 
were incubated with 20 ml of each of the heat-inactivated rabbit sera for 1 h at 37˚C to allow allergen-IgE complex formation in triplicates. Five microliters of EBV-transformed B cells (i.e., 100,000 cells/sample) were added to each of these aliquots and incubated for 30 min at room temperature. After washing with facilitated allergen-binding (FAB) assay buffer, cells were incubated with 20 ml PE-labeled anti-IgE (MACS; Miltenyi Biotec, Bergisch Gladbach, Germany) in a 1:30 dilution for 30 min at room temperature. IgE binding was analyzed by flow cytometry after washing with FAB buffer, as described (36) (37) (38) . Results are displayed as mean 6 SD of triplicate measurements.
Results
Construction, purification, and biochemical characterization of rPreS fusion proteins containing Bet v 1-derived peptides Peptides PA and PB (Fig. 1A) from the IgE epitope-containing area of the major birch pollen allergen Bet v 1 (26) were incorporated in the birch pollen allergy vaccine. PA and PB comprise aa 30-74 and aa 60-104 of Bet v 1, respectively, and, thus, include three non-IgE-reactive peptides (i.e., P29, P39, P49, Fig. 1A) , which, after coupling to keyhole limpet hemocyanin, induced Bet v 1-specific blocking IgG Abs after immunization of animals (25) . PA and PB are outside of the major Bet v 1-specific T cell epitopecontaining areas, which have been mapped to the C-terminal portion of Bet v 1 (39) . Following the hapten-carrier principle described by Benacerraf and colleagues (40), which we also used for the construction of a hypoallergenic vaccine for cat allergy (28), we produced fusion proteins consisting of different numbers and combinations of the Bet v 1-derived peptides PA and PB and the PreS surface Ag of hepatitis B (Fig. 1B) . These fusion proteins were thought to induce IgG Abs specific for the peptides and, thus, for Bet v 1, as well as for PreS, mainly with T cell help derived from epitopes of PreS. In total, we constructed, expressed, and purified four rPreS fusion proteins in E. coli: two had either one copy of PA or PB fused to the N and C terminus of PreS (i.e., 2PA-PreS, 2PB-PreS, Fig. 1B) , one had two copies of PA fused to the N and C terminus of PreS (i.e., 4PA-PreS, Fig.  1B) , and one contained two copies of PA and two copies of PB fused to the N and C terminus, respectively (i.e., 2PAPB-PreS, Fig. 1B) . The four recombinant fusion proteins were expressed with good yields in E. coli (i.e., ∼10 mg/l culture) mainly in the inclusion body fraction and could be purified to homogeneity by nickel affinity chromatography as proteins that, after reconstitution in physiological buffers, were soluble up to concentrations of 1 mg/ml. Fig. 2A shows an SDS-PAGE containing the purified PreS fusion proteins and PreS, which migrated at apparent molecular masses corresponding to the predicted values (Table I) . Gel-filtration experiments (i.e., size-exclusion chromatography) indicated that neither PreS nor the PreS fusion proteins formed aggregates in solution, although circular dichroism analysis showed that the proteins remained unfolded in physiological buffers (data not shown).
Using specific Ab probes for the peptides and PreS, it was shown in a nondenaturing dot blot assay that each of the proteins contained the PreS backbone and that the peptides PA and PB were accessible in the respective fusion proteins (Fig. 2B) . When dotblotted proteins were incubated only with buffer or rabbit preimmune Igs, no signals were observed (Fig. 2B) . Dot blot results were confirmed by ELISA experiments (data not shown).
rPreS fusion proteins containing Bet v 1 peptides lack IgE reactivity and allergenic activity
In a first set of experiments, we tested 47 patients with allergy to birch pollen for IgE reactivity to rBet v 1, the four PreS fusion proteins, and PreS in a nondenaturing, radioallergosorbent testbased dot blot assay (Fig. 3) . Each of the patients showed IgE reactivity of varying intensities to rBet v 1, whereas no IgE reactivity to PreS or the four PreS fusion proteins was observed (Fig.  3) . For control purposes, we also tested sera from three nonallergic individuals and buffer alone. Furthermore, HSA (negative control) was included on the membranes. Under these conditions, no binding was found (data not shown).
In a second set of experiments, 17 of the 47 sera used in the dot blot experiments (i.e., A1-A17) and sera from four additional patients allergic to birch pollen (A18-A21) were tested in an ELISA for their IgE reactivity to Bet v 1, PreS, and the four PreS fusion proteins (Table II) . None of the allergic patients showed any IgE reactivity to the four PreS fusion proteins or to PreS. Similar results were obtained with sera from the nonallergic individuals. Sera from patients allergic to birch pollen but not from the nonallergic individuals showed IgE reactivity to rBet v 1 (allergic patients A1-A21: OD 0.110-0.994; mean OD, 0.340; nonallergic individuals NA1-NA3: OD 0.014-0.031; mean OD, 0.021) ( Table II) .
Next, we compared the allergenic activity of PreS fusion proteins with rBet v 1 by measuring the upregulation of CD203c on basophils from six patients allergic to birch pollen (Fig. 4) . Incubation of blood samples with increasing concentrations (i.e., 0.00001-0.1 mg/ml) of rBet v 1 strongly upregulated CD203c expression on patients' basophils, whereas no relevant upregulation was observed with the same concentrations of the PreS fusion proteins. Anti-human IgE induced an upregulation of CD203c in each of the samples, whereas buffer alone (negative control) showed no effect (Fig. 4) . rPreS fusion proteins show reduced activation of Bet v 1-specific T cells but induced tolerogenic and Th1-like immune responses in cultured PBMCs from patients allergic to birch pollen Cultured PBMCs from patients allergic to birch pollen were exposed to rBet v 1, PA, PB, PreS, and the four PreS fusion proteins (Fig. 5A) . PA (p = 0.025) and PB (p = 0.010) induced significantly lower proliferative responses compared with rBet v 1 (Fig. 5A) . PreS and PreS fusion proteins induced comparable proliferations of lymphocytes that, therefore, were mainly specific for PreS.
We also investigated the production of 17 cytokines in the PBMC cultures (Fig. 5B, 5C ). Interestingly, we found that the PreS fusion proteins induced significantly higher levels of the tolerogenic cytokine IL-10 and the Th1 cytokine IFN-g than did Bet v 1, Bet v 1-derived peptides, or PreS (Fig. 5B, 5C ). We also noted a decreased production of the Th2 cytokine IL-5 in peptide, PreS, and PreS fusion protein-stimulated cultures compared with Bet v 1 (Fig. 5B) . Furthermore, we found that PreS fusion proteins, but not PreS, Bet v 1, or the isolated peptides, led to an increased production of certain proinflammatory cytokines linked to innate immunity (i.e., IL-1b, IL-6, TNF-a, IL-17, G-CSF) (data not shown). No relevant differences with regard to IL-8, IL-13, MIP1b, or MCP-1 were observed, and levels of IL-2, IL-4, IL-7, IL-12, and GM-CSF were low for each of the tested Ags (Fig. 5B , data not shown). 
Enhancement of allergen-specific and cross-reactive IgG responses of PreS fusion proteins through duplication and combination of fused Bet v 1 peptides
Rabbits immunized with PreS fusion proteins using different adjuvants (i.e., aluminum hydroxide, CFA) showed a strong and robust Bet v 1-specific IgG response over a wide range of serum dilutions (Fig. 6A) . IgG levels of CFA-immunized rabbits were approximately 10-fold higher than were those of alum-immunized rabbits. Interestingly, when the number of Bet v 1-derived peptides was doubled in the PreS fusion proteins (e.g., 2PA-PreS versus 4PA-PreS), a much stronger induction of Bet v 1-specific IgG was obtained (Fig. 6A) . The highest Bet v 1-specific IgG titers, which were comparable to those obtained with the complete Bet v 1 allergen, were achieved with 2PAPB-PreS, consisting of two copies of each of the peptides PA and PB fused to PreS (Fig. 6A) .
A detailed epitope mapping performed with Bet v 1-derived synthetic peptides P19-P69 (Fig. 1A) showed that immunization with alum-adsorbed complete rBet v 1 allergen induced IgG Abs recognizing each of the peptides with low intensity, thus yielding a broad immune response. In contrast, immunization with alumadsorbed PreS fusion proteins focused the IgG responses mainly toward those peptides that are derived from the major IgE-binding area of Bet v 1 (i.e., peptides P29, P39, and P49; Fig. 6B) (25, 26) . Many patients who are allergic to birch pollen also exhibit symptoms caused by Bet v 1-homologous allergens present in tree pollen and plant-derived foods (27, 41, 42 ). Therefore, we tested whether Abs induced by immunization with PreS fusion proteins also cross-react with Bet v 1-homologous allergens. Immunization with PreS fusion proteins induced IgG Abs specific for Bet v 1-homologous allergens in alder (rAln g 1), hazel (rCor a 1), and apple (rMal d 1). The broadest cross-reactivity was observed with PreS fusion proteins containing peptide PA, which exhibited the highest sequence homology among Bet v 1-related pollen and food allergens (Fig. 6C, 6D) .
Focusing of blocking IgG responses to Bet v 1 IgE epitopes by the 2PAPB-PreS-based vaccine
In the next series of experiments, we studied whether IgG Abs obtained by immunization of rabbits with alum-adsorbed 2PAPB-PreS, which had induced the highest Bet v 1-specific IgG response, could inhibit the binding of allergic patients' IgE to Bet v 1. Fig. 7 shows that anti-2PAPB-PreS IgG Abs caused a mean inhibition of allergic patients' (n = 20) IgE binding to Bet v 1 of 69.7%, which was significantly higher (p = 0.001) than that obtained with antirBet v 1 IgG Abs (i.e., 51.1%). Anti-PreS-IgG showed no inhibition (Fig. 7) .
IgG Abs induced by immunization with 2PAPB-PreS inhibit Bet v 1-specific basophil activation and IgE-facilitated allergen presentation
Furthermore, we investigated whether anti-2PAPB-PreS IgG Abs could inhibit Bet v 1-induced activation of the basophils of patients who are allergic to birch pollen. As shown in Fig. 8 , a 1:10 diluted anti-2PAPB-PreS and anti-Bet v 1 rabbit anti-serum, but not serum from a nonimmunized rabbit or a rabbit immunized with PreS (data not shown), inhibited activation of basophils from three patients who are allergic to birch pollen. Reductions in basophil activation were also observed with a 1:40 dilution of the anti-2PAPB-PreS antiserum and with a 1:80 dilution of the antirBet v 1 antiserum (data not shown).
We also studied whether anti-2PAPB-PreS Abs could inhibit IgE-facilitated allergen presentation via CD23 using the FAB assay (36) . Anti-2PAPB-PreS Abs caused a reduction .37% of IgEfacilitated allergen binding to CD23-expressing B cells, although the reduction was less than that observed with anti-Bet v 1 Abs (Fig. 9A) . Anti-PreS Abs had no effect (Fig. 9B) .
Discussion
In this study, we developed and characterized a therapeutic vaccine for the treatment of birch pollen allergy, which affects .100 million patients worldwide. The vaccine is based on the major birch pollen allergen, Bet v 1, which harbors the majority of immunologically relevant epitopes responsible for birch pollen and related pollen and food allergies (21, 22, 39) . Furthermore, rBet v 1 has been used successfully for birch pollen-specific immunotherapy and shown to replace total birch pollen extract (19) . Based on previous work identifying the major IgE-reactive sites of Bet v 1 (26), we constructed four fusion proteins consisting of a nonallergenic carrier protein, the PreS protein from hepatitis B, a component of hepatitis B vaccines (28, 43) , and different numbers and combinations of nonallergenic peptides derived from the major IgE-reactive area of Bet v 1 (Fig. 1) . According to the haptencarrier principle described by Benacerraf and colleagues (40, (44) (45) (46) , upon immunization the fusion proteins should induce IgG Abs against the allergen-derived peptides, the corresponding allergen, and the allergen-unrelated carrier molecule with T cell help from the carrier.
Testing the four fusion proteins for IgE reactivity and allergenic activity with sera and basophils of patients allergic to birch pollen showed that the PreS fusion proteins lacked any detectable IgE reactivity or relevant allergenic activity and, thus, appeared to exhibit an even lower allergenic activity than all previously described hypoallergenic versions of Bet v 1 (47) . In addition to the reduction in allergenic activity, the peptides used for construction of the fusion proteins showed a significant reduction with regard to the activation of Bet v 1-specific T cells. The latter feature may be another important advantage over previously characterized Bet v 1 hypoallergens, because the recombinant hypoallergens were made to preserve allergen-specific T cell epitopes and, hence, induced late-phase side effects during SIT and IgE-independent delayed-type inflammation in allergic patients by atopy patch testing (48, 49 ). An unexpected finding was that the fusion proteins shifted the T cell response in cultured PBMCs from patients allergic to birch pollen toward a tolerogenic and Th1 phenotype that has been described as beneficial for the modulation of allergy by SIT (3). This effect may be explained by the covalent linkage of allergen-derived peptides to the PreS protein.
Immunization of rabbits with the fusion proteins adsorbed to CFA, as well as to aluminum hydroxide, an adjuvant used in most current allergy vaccines, induced high levels of IgG Abs that were directed against the major IgE-reactive areas on the Bet v 1 allergen and cross-reacted with Bet v 1-related pollen and food allergens (27, 42) . Aluminum hydroxide is frequently added as adjuvant to enhance the immune response; furthermore, it has a depot effect that can reduce systemic side effects (8) .
Fusion proteins containing four Bet v 1-derived peptides (i.e., 2PAPB-PreS, 4PA-PreS) induced consistently higher levels of Bet v 1-specific IgG Abs than did fusion proteins containing only two copies of Bet v 1-derived peptides. The induction of allergen-specific blocking IgG has been identified as an important mechanism of SIT (3, 12, 50) . Therefore, we investigated whether Abs induced by immunization with the fusion proteins could inhibit allergic patients' IgE binding to Bet v 1. Interestingly, we found that 2PAPB-PreS-induced IgG inhibited allergic patients IgE binding to Bet v 1 significantly better than did IgG induced by immunization with the complete Bet v 1 allergen. This finding may be explained by the fact that 2PAPB-PreS focuses IgG predominantly against the IgE-reactive areas of Bet v 1, whereas immunization with Bet v 1 also induces IgG against epitopes that are not recognized by IgE. In this context, it was reported that birch pollen-specific SIT induces IgG Abs that lack blocking effects; this SIT may even have harmful effects because the Abs were reported to enhance IgE binding to Bet v 1 and Bet v 1-induced skin reactions (51, 52) . Therefore, it is tempting to speculate that a birch vaccine based on 2PAPB-PreS may have another advantage over vaccines based on Bet v 1: as a result of the focusing of IgG responses toward IgE epitopes, a 2PAPB-PreS-based vaccine may reduce the formation of unwanted and potentially harmful IgG responses during SIT. In fact, we found that 2PAPB-PreS-induced IgG had beneficial effects because these Abs inhibited Bet v 1-induced activation of allergic patients' basophils, indicating that a 2PAPB-PreS-based vaccine likely will reduce Bet v 1-induced immediate allergic inflammation.
The beneficial effects of SIT on allergen-specific T cell responses may be explained by at least two mechanisms. One possibility is the induction of allergen-specific T cell tolerance by allergen-derived T cell epitopes or linked immunological suppression (53) . The second possibility is based primarily on the induction of blocking IgG Abs that inhibit IgE-facilitated allergen presentation to T cells and, thus, lead to a suppression of T cell and proinflammatory cytokine responses (54, 55) . In fact, our study provides evidence that a 2PAPB-PreS-based vaccine may induce allergen-specific T cell tolerance by both mechanisms, because we found that the 2PAPB-PreS-based vaccine induced the tolerogenic cytokine IL-10 in PBMCs from allergic patients, and 2PAPB-PreS-induced IgG inhibited IgE-facilitated allergen binding to CD23-expressing B cells. An additional beneficial effect for allergen-specific IgG may be the induction of tolerance by the activation of the inhibitory pathway via binding on FcgRIIB (56) .
Our study thus reports the characterization of a vaccine for the treatment of birch pollen allergy based on the peptide carrier concept (i.e., 2PAPB-PreS), which holds promise for reducing immediate, as well as delayed-type, side effects better than previously described Bet v 1 hypoallergens. In addition, our study reveals novel and unexpected features of the PreS carrier-based allergy vaccines that include the highly efficient focusing of blocking IgG toward IgE epitopes and their potential to modulate allergen-specific T cell responses toward a tolerogenic type. 
